摘要
目的：本研究旨在通过观察2型糖尿病患者尿Smad1的排泄水平，探讨尿Smad1对糖尿病肾病诊断方面的临床意义。方法选择来自广州中医药大学第一附属医院内分泌科和暨南大学第一附属医院内分泌科166例2型糖尿病患者。将他们按尿微量白蛋白与肌酐比值（ACR）分为正常白蛋白尿组(NAU)、低值白蛋白尿组(LAU)、高值白蛋白尿组(HAU)、极高值白蛋白尿组(VHAU)。其中，LAU、 HAU和VHAU作为糖尿病肾病组，NAU作为糖尿病非肾病组，并以80例健康体检者作为对照组。采用酶联免疫吸附法（Elisa）检测尿标本中Smad1浓度，并以尿Smad1与肌酐比值（SCR）作为标准数值，SCR取对数值。结果1.糖尿病肾病组SCR较糖尿病非肾病组高，差异有统计学意义(P<0.05)，而糖尿病非肾病组SCR与对照组无明显差异（P>0.05）。2.LAU组SCR与NAU组没有明显差别（P>0.05）。3.VHAU组SCR较HAU组和LAU组高，HAU组较LAU组高，差异有统计学意义（P<0.05）。结论本研究表明尿Smad1可以作为2型糖尿病肾病诊断的新型指标，但不能预测早期糖尿病肾病。
Abstract
Objective The aim of this study was to analyze urinary Smad1level in patients with type 2diabetes, explore the possibility of Smad1being a indicator for early diagnosis. Methods 166 subjects with type 2diabetes and 80 healthy volunteers were enrolled. Subjects were grouped according to urine albumin to creatinine ratio(ACR) into: normal albumin in urine (NAU), low albumin in urine (LAU), high albumin in urine (HAU), and very high albumin in urine (VHAU). Among those, LAU, HAU, and VHAU were regarded as the diabetic nephropathy group(DN group), NAU was regarded as nondiabetic nephropathy(non-DN group), and the healthy volunteers were the controls. Enzyme-linked immunosorbent assay was used todetect the urinary Smad1concentration, urinary Smad1to creatinine ratio (SCR) was used as the standard reference. Results Compared with non-DN group, SCR of DN group was higher (P<0.05), while there was no difference between the non-DN group and controls (P>0.05). There was no significant difference for SCR between LAU and NAU groups (P>0.05). The SCR was higher in VHAU groupthan those in HAU and LAU groups, and higher in HAU than that in LAU group (P<0.05). Conclusion It suggested that the urinary Smad1may be a new potential diagnostic indicator for DN. However, it cannot predict the earliest DN.
NETL
NSTL
维普
万方数据